Please Scroll Down to See Forums Below 
.jpg "Research Chemical Sciences")
.png "Research Chemical Sciences")
Good post.. but I did spot an error. Yohimbine HCL is legal in the United States to take orally in single doses of 2.9mg or less hence it's availability in many OTC supplements... FDA law only stipulates that a prescription is required for yohimbine HCL products having above 2.9mg per single dose. I also have some disagreements with a few statements. For example...
"HOW DOES YOHIMBINE WORK?
It binds to the A2 and blocks Norepinephrine(and other A2 agonist INCLUDING ESTROGEN) from binding to and agonizing it (which inhibits the release of fatty acids)- thus it allows for fatty acids to be "burned" and thus stubborn fat to be lost. "
This describes only a small part of yohimbine's lipolytic mechanisms. There is strong evidence to believe that the A2 adrenoceptor blocking activity plays only a very small part due to the indifference displayed in the fat loss of patients with varying A2 concentration (1),
and that the primary mechanism is attributable to the increase in synaptic norepinephrine with a resultant increment in lipolysis by beta adrenergic agonism. (2)
1. Berlan M, Galitzky J, et al. Plasma Catecholamine Levels and Lipid Mobilization Induced by Yohimbine in Obese and Non-obese Women. Int J Obes 1991 May;15(5):305-315.
2. KucGalitzky J, Vermorel M, Lafontan M, Montastruc P. Thermogenic and Lipolytic Effect of Yohimbine in Canines. Brit J Pharmacol 1991 Oct;104(2):514-518.
"HOW DOES YOHIMBINE WORK?
It binds to the A2 and blocks Norepinephrine(and other A2 agonist INCLUDING ESTROGEN) from binding to and agonizing it (which inhibits the release of fatty acids)- thus it allows for fatty acids to be "burned" and thus stubborn fat to be lost. "
This describes only a small part of yohimbine's lipolytic mechanisms. There is strong evidence to believe that the A2 adrenoceptor blocking activity plays only a very small part due to the indifference displayed in the fat loss of patients with varying A2 concentration (1),
and that the primary mechanism is attributable to the increase in synaptic norepinephrine with a resultant increment in lipolysis by beta adrenergic agonism. (2)
1. Berlan M, Galitzky J, et al. Plasma Catecholamine Levels and Lipid Mobilization Induced by Yohimbine in Obese and Non-obese Women. Int J Obes 1991 May;15(5):305-315.
2. KucGalitzky J, Vermorel M, Lafontan M, Montastruc P. Thermogenic and Lipolytic Effect of Yohimbine in Canines. Brit J Pharmacol 1991 Oct;104(2):514-518.
Last edited:
